1. |
Prevalence of multidrug-resistant TB'alarmingly high' |
|
Inpharma Weekly,
Volume &NA;,
Issue 1286,
2001,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
2. |
Thalidomide in cancer reviewed |
|
Inpharma Weekly,
Volume &NA;,
Issue 1286,
2001,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
3. |
Prostate cancer: initial treatment affects later costs |
|
Inpharma Weekly,
Volume &NA;,
Issue 1286,
2001,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
4. |
Invasive TACTIC superior after tirofiban in ACS |
|
Inpharma Weekly,
Volume &NA;,
Issue 1286,
2001,
Page 5-6
Charles Bankhead,
Preview
|
|
摘要:
Last year at the American Heart Association meeting, data from the TACTICS-TIMI*18 clinical trial showed the superiority of an early invasive strategy in patients with acute coronary syndromes (ACS) who had previously received medical therapy with aspirin, heparin, β-blockers and the glycoprotein IIb/IIIa receptor antagonist tirofiban ['Aggrastat'].1**Compared with a conservative strategy, the invasive strategy significantly reduced the risk of the composite endpoint of death, myocardial infarction (MI) and repeat hospitalisation with worsening chest pain, at 6 months. At the 50th Scientific Session of the American College of Cardiology [Orlando, US; March 2001], US cardiologist Dr William Weintraub presented the results of a prospective economic analysis of TACTICS-TIMI 18 which showed that the benefits of the invasive strategy were achieved with no appreciable increase in cost.2A related study showed that evaluation of patients with ACS using an assay for the cardiac enzyme troponin T can increase the proportion of patients who might benefit from invasive treatment.3
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
5. |
Oral treatment of onychomycosis pays off in the long run |
|
Inpharma Weekly,
Volume &NA;,
Issue 1286,
2001,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
6. |
Omapatrilat improves vascular function in heart failure |
|
Inpharma Weekly,
Volume &NA;,
Issue 1286,
2001,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
7. |
Antiangiogenesis news from the 92nd Annual Meeting of the American Association for Cancer ResearchNew Orleans, US March 2001 |
|
Inpharma Weekly,
Volume &NA;,
Issue 1286,
2001,
Page 8-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
8. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1286,
2001,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
9. |
Daptomycin - fighting against resistant Gram-positive infections |
|
Inpharma Weekly,
Volume &NA;,
Issue 1286,
2001,
Page 10-11
Pamela A Hunter,
Preview
|
|
摘要:
The first phase III clinical data on daptomycin ['Cidecin'] have recently been released, showing that the agent has similar efficacy to standard antibacterials in the treatment of complicated skin and soft tissue infections caused by Gram-positive bacteria. Furthermore, patients who achieved clinical success with daptomycin required fewer days of IV therapy than those who received standard antibacterials (vancomycin or a semisynthetic penicillin). The data were reported at the 11th European Congress on Microbiology and Infectious Diseases [Istanbul, Turkey; April 2001].
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
10. |
Typhoid conjugate vaccine could be an'exciting advance' |
|
Inpharma Weekly,
Volume &NA;,
Issue 1286,
2001,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|